Episode details
Available for over a year
Peter White asks the Macular Disease Society for their reaction to Novartis's decision to seek a judicial review into the use by 4 PCTs of the drug Avastin, which is being used off-label to treat people with Age-related Macular Degeneration. As the regulator NICE has not issued any guidance to PCTs, as the drug is not licensed for use in the eye, the decision to use it currently rests with clinicians. The programme asks what the significance is of the judicial review and the possible consequences for people with AMD seeking treatment in the future. Lee Kumutat joins a ballet workshop designed to give blind people an enhanced experience of the performance. Lee finds herself doing a pirouette when she least expected it and talks to other VIPs about their experience of the hands-on workshop.
Programme Website